Company Encyclopedia
View More
name
SPDR S&P Em S-Cap
EWX.US
News
View More

Structure Therapeutics Raises $747.5 Million in Upsized Public Offering Including Full Exercise of Underwriters’ Option

Structure Therapeutics Inc. has completed an upsized public offering, raising approximately $747.5 million. The offering included 9,961,538 American depositary shares (ADSs), pre-funded warrants for 1,538,462 ADSs, and the full exercise of underwriters' option for an additional 1,500,000 ADSs. The proceeds are before expenses. This information was originally published by Structure Therapeutics via GlobeNewswire.

Reuters·
US
GPCR
-0.56%
Reuters·
US
GPCR
-0.56%

Owner FMR LLC Sells 52,356 ($3.8M) Of Structure Therapeutics Inc [GPCR]

FMR LLC Beneficial Owner of Structure Therapeutics Inc [GPCR] filed a Form 4 on December 10, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/8/25TransactionSaleShares52,356Price$71.98Value$3,768,433Ending Holdings: 1 - IndirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Reuters·
US
GPCR
-0.56%
Reuters·
US
GPCR
-0.56%

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants | GPCR Stock News

Structure Therapeutics Inc. announced the pricing of its upsized $650 million public offering of ADSs and pre-funded warrants. The offering includes 8,461,538 ADSs at $65.00 each and pre-funded warrants for 1,538,462 ADSs at $64.9999 each. The offering is expected to close on December 11, 2025, with Jefferies, Leerink Partners, Goldman Sachs, Morgan Stanley, Guggenheim Securities, and BMO Capital Markets as joint book-running managers.

StockTitan·
US
GPCR
-0.56%
StockTitan·
US
GPCR
-0.56%

In the 'uber bull' biotech market, is Structure the next Metsera?

In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.

MSN·
US
GPCR
-0.56%
MSN·
US
GPCR
-0.56%

Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk

Structure Therapeutics' stock surged 102.49% after its obesity pill aleniglipron showed superior results in trials compared to Eli Lilly and Novo Nordisk's offerings. Analysts praised the pill's performance and safety profile, with price targets raised significantly. The pill is expected to enter the market by 2028 and generate $6.3 billion in sales by 2040. Analysts maintain a Strong Buy consensus on the stock, with an average price target reflecting over 20% upside.

Tip Ranks·
US
GPCR
-0.56%
Tip Ranks·
US
GPCR
-0.56%
© 2025 Longbridge｜Disclaimer